Join our daily newsletter At The Bell to receive exclusive market insights
- Biotechnology company Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a preliminary safety and efficacy review
- The study is evaluating a combination of Immutep’s lead product candidate, efti, with MSD’s KEYTRUDA in patients with head, neck and lung cancers
- Following the review and recommendation by the data monitoring committee, Immutep has begun recruiting an additional 13 second-line non-small cell lung cancer patients to form stage two of Part B
- The trial is being conducted at 12 centres in Australia, Europe, the U.K. and the U.S.
- Shares last traded at 31.5 cents
Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a recommendation from the data monitoring committee.
The biotechnology company will recruit an additional 13 patients with second-line non-small cell lung cancer (NSCLC) to form stage two of Part B.
It comes after a preliminary safety and efficacy review of stage one of Part B by the data monitoring committee.
The study is being conducted in collaboration with MSD, testing the efficacy of a combined treatment in patients with second line head and neck squamous cell carcinoma or NSCLC in first and second line.
Immutep’s lead product candidate eftilagimod alpha, or simply efti, is being trialled with MSD’s KEYTRUDA, or pembrolizumab.
The trial is being conducted at 12 centres in Europe, the U.K., the U.S. and Australia.
Part A enrolled patients with NSCLC and PD-X naive, Part B enrolled second-line NSCLC and PD-X refectory patients, and Part C will recruit second-line head and neck squamous cell carcinoma and PD-X naive patients.
Shares last traded at 31.5 cents.
